Navigation Links
David Hsia, Ph.D. Joins Kinex Pharmaceuticals' Board of Directors
Date:9/15/2008

BUFFALO, N.Y., Sept. 15 /PRNewswire/ -- Kinex Pharmaceuticals announced that David Hsia, Ph.D. has been appointed to the Company's Board of Directors.

Dr. Hsia is a pharmaceutical veteran. He is a co-founder of Watson Pharmaceuticals, a publicly traded company listed in New York Stock Exchange (ticker: WPI). He was formerly Senior Vice President, Scientific Affairs of Watson Pharmaceuticals before his retirement. He has been involved in the development of various pharmaceutical formulations for over twenty years. Dr. Hsia received a Ph.D. in Industrial and Physical Pharmacy from Purdue University in 1975.

"Dr. Hsia is well known for his expertise in pharmaceutical development in our industry," commented Dr. Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "As the Company moves forward, we look forward to leveraging the full breadth of David's expertise as a Board member to assist us in developing our new drug candidates," Commented Dr. Johnson Lau, Executive Chairman of the Board.

"I am delighted to have a chance to work with the team at Kinex. The company's pipeline is very strong and I am glad to have this opportunity to assist to further advance their product pipeline," commented Dr. Hsia.

About Kinex Pharmaceuticals

Kinex is a drug discovery and development company that is focused on the use of its platform technology and compound libraries to identify and develop peptide-competitive kinase inhibitors. The Company's clinical compound KX2-391 is a selective Src kinase inhibitor that is currently in Phase 1 trials for oncology. Kinex's pipeline is focused on selective inhibitors for kinase targets that are important in oncology and inflammation and immunology. The Company is located in the New York State Center of Excellence in Bioinformatics and Life Sciences, on the Buffalo Niagara Medical Campus in Buffalo, New York.


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
2. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
3. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
4. Omeros Appoints David A. Mann to its Board of Directors
5. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
6. David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager
7. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
8. David M. Stout Joins NanoBio Corporations Board of Directors
9. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
10. Abingworth Appoints David Mayer as Partner
11. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... 2016 The Biotech industry continues to ... that there are no opportunities ahead. Today, ActiveWallSt.com has on ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ... Corp. (NASDAQ: OPHT ). Sign up now to ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained ...
(Date:5/17/2016)... -- Haselmeier announces the launch by Merck ... EMA, the European Medicines Agency. Originally launched in 2011 ... new pen version includes enhancements to further improve the ... patients during use. Its enhanced design has ... with a larger display window that improves the readability ...
(Date:5/17/2016)... BASEL, Switzerland , May 17, 2016 /PRNewswire/ ... sciences company located in Basel, Switzerland ... an investigational oral inhibitor of P38 mitogen-activated protein ... ) , Strekin will build the ... Pamapimod in indications in which MAP Kinases play ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):